Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625320 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
- Active
- Registry status
- Phase 3
- Development phase
- 501
- Enrollment target
- 20
- Study locations
NCT06625320: Active Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Revolution Medicines.
NCT06625320 is a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Revolution Medicines. The registered enrollment target is 501 participants, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06625320, a Phase 3 study of Pancreatic Cancer and PDAC - Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Revolution Medicines.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 501 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
Primary Outcome
PFS is defined as the time from randomization until disease progression or death from any cause, whichever occurs first. Progression is per response evaluation criteria in solid tumors (RECIST) v1.1 and as assessed by blinded independent central review (BICR)
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Irinotecan
- DRUG nab-paclitaxel
- DRUG RMC-6236
- DRUG Liposomal irinotecan
Study Locations (20)
California
- City of Hope-Duarte - Duarte
- Cedars-Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- UC San Diego Health Moores Cancer Center - San Diego
- Mission Hall UCSF - San Francisco
Florida
- Mayo Clinic Cancer Center - Florida - Jacksonville
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- Cancer Care Centers of Brevard Inc - Palm Bay
- Moffitt Cancer Center - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Cancer Center - Phoenix - Phoenix
Michigan
- University of Michigan - Ann Arbor
- Karmanos Cancer Institute - Detroit
Colorado
- Rocky Mountain Cancer - Aurora
Hawaii
- The Queen's Medical Center - Honolulu
Illinois
- The University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What the registry record for NCT06625320 still lists
NCT06625320 is an interventional study that assigns participants to a tested intervention. The registered 501 participants enrollment target is mid-sized for trials with a published cap, above the 391-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (28% higher).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT06625320 names 20 study sites across 11 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06625320 about?
NCT06625320 is a clinical study titled "Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)". The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
What is the current status of trial NCT06625320?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 501 participants. The study started on 2024-10-16. Estimated completion is 2027-12.
What conditions does trial NCT06625320 study?
This clinical trial studies the following conditions: Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, PDAC.
What interventions are being tested in trial NCT06625320?
The interventions under investigation include: Gemcitabine (DRUG), Irinotecan (DRUG), nab-paclitaxel (DRUG), RMC-6236 (DRUG), Liposomal irinotecan (DRUG).
Who is sponsoring clinical trial NCT06625320?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625320 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06625320's enrollment target sits among peer trials
501 29th of 278 higher than 250 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
RECRUITING · Phase 3
-
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
-
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04442022 · 501 participants · Phase 2
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- NCT06934525 · 501 participants · NA
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
- NCT05646381 · 502 participants · Phase 2
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
- NCT05897632 · 502 participants · NA
CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI